Roivant Sciences Ltd.
ROIV
#919
Rank
$26.545 B
Marketcap
United Kingdom
Country
$36.75
Share price
4.26%
Change (1 day)
165.82%
Change (1 year)
Categories
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated…
Key Metrics
Trailing P/E
—
Forward P/E
-23.35
EPS (TTM)
$-0.47
Forward EPS
$-1.72
Price / Book
6.85
EV / EBITDA
-19.0x
Beta
1.12
Dividend Yield
—
Return on Equity
-8.52%
Return on Assets
-16.48%
Debt / Equity
2.18
Current Ratio
16.72
Gross Margin
0.00%
Operating Margin
-25408.11%
Net Profit Margin
0.00%
Free Cash Flow
$-1,127,230,080
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
+7.25%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$8.260M
Latest Net Income$-299,771,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Roivant Sciences Ltd. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
ROIV
No recent news available. Set FINNHUB_API_KEY to enable news.
